|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Amiloride#Contraindications]] |
| {{Aminocaproic acid}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Contraindications==
| |
| | |
| AMICAR should not be used when there is evidence of an active intravascular clotting process.
| |
| | |
| When there is uncertainty as to whether the cause of bleeding is [[primary fibrinolysis]] or [[disseminated intravascular coagulation]] ([[DIC]]), this distinction must be made before administering AMICAR
| |
| .
| |
| | |
| The following tests can be applied to differentiate the two conditions:
| |
| | |
| Platelet count is usually decreased in [[DIC]] but normal in [[primary fibrinolysis]].
| |
| | |
| Protamine paracoagulation test is positive in [[DIC]]; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of [[primary fibrinolysis]].
| |
| | |
| The euglobulin clot Iysis test is abnormal in [[primary fibrinolysis]] but normal in [[DIC]].
| |
| | |
| AMICAR must not be used in the presence of [[DIC]] without concomitant [[heparin]].<ref>{{Cite web | last = | first = | title = DailyMed: Search | url = http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=Aminocaproic+acid&x=-1148&y=-229 | publisher = | date = | accessdate = 31 January 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antifibrinolytics]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Amino acids]]
| |
| [[Category:Antifibrinolytics]]
| |
| [[Category:Hematology]]
| |
| | |
| [[ja:Ε-アミノカプロン酸]]
| |
| [[pl:Kwas ε-aminokapronowy]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |